Skip to content
Menu

IceCure Medical Ltd ICCM

Full chart Compare
Set alert

Price alert · ICCM

All alert types
0.76 USD -0.24 (-23.67%)

As ofNov 20, 2026, 12:50 PM EST

0.7611 Day range 0.8561
0.65 52-week range 22.20
YTD
-95.84%
1 year
-96.09%

Fundamental scorecard

8 of 25 checks passed on ICCM’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 2 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Jun 30, 2026.

Value 2 of 5

  • Failed:P/E below its own 5-year median No profit over the last 12 months, so no P/E.
  • Failed:P/E under 20 No profit over the last 12 months, so no P/E.
  • Passed:Price to sales below its own 5-year median Price to sales 1.1 against a 5-year median of 18.3.
  • Passed:Price to book below its own 5-year median Price to book 0.4 against a 5-year median of 4.0.
  • Failed:Free cash flow yield above 4% Free cash flow of -15.9M is -372.1% of the market value.

Growth 2 of 5

  • Passed:Revenue grew over the last year Revenue of 3.95M is +41.6% on the 12 months before.
  • Failed:Revenue grew more than 5% a year over five years -2.7% a year from FY 2020 to FY 2025.
  • Passed:Earnings per share grew over the last year EPS -6.77 against -8.39 in the 12 months before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -6.60 in FY 2020, -7.20 in FY 2025.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 1 of 5

  • Failed:Profitable over the last year Net income of -16.9M over the last 12 months.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -228.3%.
  • Passed:Net margin above its 5-year average Net margin of -427.7% against a 5-year average of -430.9%.
  • Failed:Free cash flow is at least 80% of net income No profit over the last 12 months to compare with.

Financial health 3 of 5

  • Passed:Short-term assets cover short-term liabilities Short-term assets of 16.6M against short-term liabilities of 5.79M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 16.6M against long-term liabilities of 21.0K.
  • Passed:Net debt under 40% of equity More cash than debt: 12.0M of cash against 90.0K of debt.
  • Failed:Operating cash flow covers at least 20% of debt Operating cash flow of -15.9M is -17635.6% of debt.
  • Failed:Operating profit covers interest at least 3 times Operating profit is -106.5 times the interest expense.

Dividend No data

  • No data:Pays a dividend Not enough data to decide.
  • No data:Yield above 1.5% Not enough data to decide.
  • No data:Pays out under 75% of profit Not enough data to decide.
  • No data:Covered by free cash flow Not enough data to decide.
  • No data:Not cut in the last five fiscal years Not enough data to decide.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What ICCM owns and owes, as of Jun 30, 2026

Short term and long term

Balance sheet · 17.7M of assets

Debt, equity and cash by year

Now: 11.9M more cash than debt

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

-15.99 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

2 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

C2 / 5 overall

  • DCF 1
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 3
  • P/E 1
  • P/B 3

Valuation

P/E -2.6×
P/S 11.5×
P/B 4.3×
P/FCF -2.7×
EV/EBITDA -2.0×
EV/Sales 8.9×
FCF Yield -37.7%

Profitability

Gross Margin 36.3%
Operating Margin -446.7%
Net Margin -445.6%
ROE -166.4%
ROIC -162.9%
ROA -108.4%

Growth (YoY)

Revenue 2.7%
Operating Income 3.8%
EPS (diluted) 21.1%
Free Cash Flow -15.6%

Financial Health

Current Ratio 2.6×
Quick Ratio 2.1×
Debt / Equity 0.0×
Net Debt / EBITDA 0.6×
Interest Coverage 0.0×

Dividends

Dividend Yield 0.0%
Payout Ratio 0.0%

Annual · latest fiscal year ends 2025-12-31